Answer
Headache and dizziness were both classified as uncommon in previously treated patients with severe haemophilia A receiving Elocta (efmoroctocog alfa) in clinical trials.
Sources for this answer
- ELOCTA 250 IU powder and solvent for solution for injectionSwedish Orphan Biovitrum Ltd · emc · SmPC §4.8 Undesirable effects · Version 11Document updated
Sources checked